MOH Stock Plunges On Shock Earnings Miss And Drastic 2026 Guidance Cut
Molina Healthcare (MOH) – a managed healthcare provider for Medicaid and Medicare beneficiaries – hit a 6-day winning streak, with cumulative gains over this period amounting to 23%. The company’s market cap has surged by about $1.4 Bil over the last 6 days and currently stands at $7.7 Bil.
The stock has YTD (year-to-date) return of 13.0% compared to 0.9% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Rally?
[1] Q4 2025 Earnings Miss & Weak 2026 Guidance
- Snowflake’s AI Bet Is Working—So Why Is The Stock Down?
- Alcoa Hits Pause After A Strong Run — What Changed?
- Johnson & Johnson Stock Surged 60%, Here’s Why
- How Amazon Stock Behaves During Market Shocks
- Is Philip Morris International Stock Undervalued Stock Or Value Trap?
- Will Musk’s $1.6 Trillion Disruption Be His Biggest Yet?
- Reported adjusted Q4 loss of $2.75 per share vs. expected profit [7, 10, 15]
- 2026 EPS guidance of at least $5.00, far below consensus of $13.71 [4, 10]
- Impact: Stock collapsed over 30% after hours, Heavy selling volume
[2] Widespread Analyst Downgrades and Price Target Cuts
- Wells Fargo downgraded stock to Equal Weight, slashing price target [1, 2]
- Multiple firms including Goldman Sachs, Barclays, and Jefferies cut targets [2, 3, 12]
- Impact: Sustained downward price pressure, Reinforced negative institutional sentiment
Opportunity or Trap?
Below is our take on valuation.
There is a near-equal mix of good and bad in MOH stock given its overall Moderate operating performance and financial condition. Considering stock’s Low valuation we think it is Attractive (For details, see Buy or Sell MOH).
But here is the real interesting point.
You are reading about this 23% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Returns vs S&P 500
The following table summarizes the return for MOH stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MOH | S&P 500 |
|---|---|---|
| 1D | 1.9% | 0.7% |
| 6D (Current Streak) | 23.1% | -0.5% |
| 1M (21D) | -22.4% | 0.5% |
| 3M (63D) | 6.9% | 4.4% |
| YTD 2026 | -13.0% | 0.9% |
| 2025 | -40.4% | 16.4% |
| 2024 | -19.4% | 23.3% |
| 2023 | 9.4% | 24.2% |
However, big gains can follow sharp reversals – but how has MOH behaved after prior drops? See MOH Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 64 S&P constituents with 3 days or more of consecutive gains and 32 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 36 | 13 |
| 4D | 10 | 15 |
| 5D | 13 | 0 |
| 6D | 4 | 2 |
| 7D or more | 1 | 2 |
| Total >=3 D | 64 | 32 |
Key Financials for Molina Healthcare (MOH)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $40.6 Bil | $45.4 Bil |
| Operating Income | $1.7 Bil | $781.0 Mil |
| Net Income | $1.2 Bil | $472.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $11.5 Bil | $11.4 Bil |
| Operating Income | $137.0 Mil | $-162.0 Mil |
| Net Income | $79.0 Mil | $-160.0 Mil |
While MOH stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.